Rethinking Myasthenia Gravis: A global perspective on ABN's latest guidelines

Échec de l'ajout au panier.

Veuillez réessayer plus tard

Échec de l'ajout à la liste d'envies.

Veuillez réessayer plus tard

Échec de la suppression de la liste d’envies.

Veuillez réessayer plus tard

Échec du suivi du balado

Ne plus suivre le balado a échoué

Rethinking Myasthenia Gravis: A global perspective on ABN's latest guidelines

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

In this special international episode, we explore the 2025 update of the Association of British Neurologists’ guidelines on managing autoimmune myasthenia gravis. Ten years after the previous recommendations, significant changes have been introduced. We emphasise the importance of daily steroids, early thymectomy, rituximab, and emerging targeted therapies transforming patient care. We also examine how these updates influence frontline care in the UK, Australia, and the USA, and why a multidisciplinary approach remains vital in the management of MG.

Participants:

Professor Alasdair Coles is Head of Department for Clinical Neuroscience and also Co-Director of the Cambridge Centre for Myelin Repair, UK.
Associate Professor Katherine Buzzard, Clinical Lead, Eastern Health Multiple Sclerosis and Neuroimmunology Service, Melbourne, Australia.
Dr. Christopher Doughty, MD is a board-certified neurologist, and affiliated with Brigham and Women's Hospital, in Boston, Massachusetts, USA.

Read the paper (https://pn.bmj.com/content/25/5/422), which is part of the October issue of the Practical Neurology journal.

Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol.

Production and editing by Letícia Amorim. Thank you for listening.

Pas encore de commentaire